Romlusevimab
Based on 1 Customer Validation
Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 95.00%
- CAS No.: 2509447-08-7
- 분자량:145.126 kDa
-
보관:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
IC50 & Target
Severe acute respiratory syndrome coronavirus 2
In Vitro
Romlusevimab and Amubarvimab (HY-P99435) bind to distinct epitopes of the SARS-CoV-2 spike protein[1].
Romlusevimab has an additive effect when combined with Amubarvimab[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
신청
ELISA, FACS, Functional assay
Product Details
-
CAS No. 2509447-08-7
-
Accession P59594
-
Gene ID 43740600 [NCBI]
-
Synonyms BRII-198
-
분자량 145.126 kDa
-
Species Reactivity
Virus
-
Conjugated
Unconjugated
-
Isotype
Human IgG1 lambda2
-
Recommend Isotype Controls
-
Format
-
Human IgG1 lambda2
-
Product Properties
-
Appearance
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Purity
95.00%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
-
선적
Shipping with dry ice.
순도&문서
References
[1]. Hoy SM. Amubarvimab/Romlusevimab: First Approval. Drugs. 2022 Aug;82(12):1327-1331. [Content Brief]
[2]. Ji Y, et al. Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2. Front Immunol. 2022 Sep 14;13:980435. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)